We are missing the financial data our models need for this company. It will appear once the data arrives.
Not valued: none of the models for this type of company has positive earnings, cash flow or book value to work with.
ACCE opinionDiversified Healthcare Trust Common Shares of Beneficial Interest (DHC)
Fair value
Not available
ACCE price target
$7.80
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $7.86 at the close on 23 Oct 2026, 22:00 CEST.
Models: EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
32
out of 100
Analysts
60% buy
5 covering
P/E
0.0x
forward 16.6x
1-year return
+82.8%
Dividend yield
0.52%
Diversified Healthcare Trust Common Shares of Beneficial Interest in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Diversified Healthcare Trust owns a portfolio of senior living communities, medical office buildings and life science properties, with much of the senior housing operated by third-party managers under contracts with the trust. The case for a closer look rests on the gap between the company's trough earnings and its forward multiple: trailing P/E is not meaningful, yet the forward P/E sits at 16.6, which implies the market expects a sharp recovery in operating income. Revenue fell 4.5% and operating margin is essentially break-even at -0.1%, with a gross margin of 18.6%, so the thesis depends on occupancy and operating leverage returning rather than on any structural advantage. The score of 36/100 and the absence of index membership reflect that weakness, and the balance sheet and asset sales would need separate work before any view on recovery could be formed. A portfolio manager should look here only if they are prepared to underwrite a turnaround in senior housing fundamentals.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Earnings collapse and losses
Earnings fell 68.4% year on year, net margin is -17.7% and ROE is -15.5%. Free cash flow was $-19,618,000, so the business is losing money and burning cash.
high
Leverage and cash burn
Debt/Equity is 1.45 and free cash flow is negative at $-19,618,000. Less cash headroom means limited room to absorb further revenue decline.
moderate
Shrinking revenue
Revenue is down 4.5% year on year and the 5-year revenue CAGR is -1.2%. Top-line weakness has persisted beyond one bad quarter.
AI research notes
AI-assisted·How I use AIWritten Oct 19, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Three of five analysts rate the shares Buy or Strong Buy, and their mean price target sits well above the current price.
Latest quarter's earnings per share beat expectations by 14.3%, coming in at 0.16 against 0.14 expected.
At a forward P/E of 16.6x, the shares are priced below many peers, leaving room for a rerating if earnings recover.
Why it could disappoint
Free cash flow over the last twelve months was negative at -$20M, so the business is not generating cash to pay down debt.
Debt to equity of 1.45 leaves little room to absorb a refinancing shock, and maturing debt in a higher-rate market could force asset sales.
Revenue fell 4.5% year over year and net margin was -17.7%, so the business is shrinking and losing money on each dollar of sales.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 2, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where DHC's valuation models land
Price
$7.86
Model
Fair value
Upside
EV/EBITDA comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
+Quarter-over-quarter institutional position changes
+Every insider and Congress trade, with how late it was disclosed
+Active 13D activist filings and top holders
Compare
Where it sits vs peers
News and Record
Press releases mentioning this company
Recent performance
1 week
+3.6%
1 month
-3.3%
3 months
-15.8%
6 months
+5.4%
YTD
+62.1%
1 year
+82.8%
SEC filings
Recommendation history, last 12 months
Date
Type
New
Previous
Price
11 Oct 2026, 00:00 CEST
ACCE price target
$7.80
first publication
$7.50
Price
+82.8% · 1Y
Ask anything about DHC
Answered from Diversified Healthcare Trust Common Shares of Beneficial Interest fundamentals + recent valuations. Every number shows its source and date.
This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 78.2x
ROEbetter than 0% of peers
low -15%-15%high 12%
Div yieldbetter than 0% of peers
low 0.5%0.5%high 13.3%
Peers
Prices Oct 23, 2026
Company
Price
Fair value
vs fair value
P/E
ROE
Quality
Score
DHCDiversified Healthcare Trust Common Shares of Beneficial Interest